Good
Mostly Aligned
Patient Risk:
Moderate
Summary
Most statements align with the label (deep IM gluteal administration, alternating buttocks, 4-week dosing, opioid-free requirements, and opioid withdrawal risk). Several administration-technique details and peripheral safety claims about infection risk/failed dosing are not specifically supported by the provided label excerpts, and a few labeling nuances (dose preparation by healthcare provider; timing details for opioid withdrawal prevention) are more specific on-label than the claims.
Category Scores
Accurate Statements
Vivitrol (naltrexone) is administered as an extended-release intramuscular (IM) injection.
Label indicates VIVITROL is administered as a deep intramuscular gluteal injection every 4 weeks (Section 2.1).
Vivitrol is administered as a depot formulation.
On-label administration is described as deep IM gluteal injection of VIVITROL every 4 weeks (Section 2.1).
Correct IM injection requires correct needle length, correct angle, and correct handling of the suspension so the dose is delivered correctly.
Label requires preparation and administration by a healthcare provider and specifies only deep intramuscular gluteal injection (Section 2.1). (Specific needle length/angle/suspension-handling details not shown in provided excerpts.)
The injection sites should be alternated if multiple doses are needed.
Label: alternating buttocks for each subsequent injection (Section 2.1).
Vivitrol is commonly prescribed as a monthly injection (every 4 weeks) for alcohol use disorder maintenance treatment.
Label: indicated for alcohol dependence; recommended dose 380 mg every 4 weeks (Section 1.1 and Section 2.1).
Vivitrol is commonly prescribed as a monthly injection (every 4 weeks) for opioid use disorder maintenance treatment.
Label: indicated for prevention of relapse to opioid dependence following opioid detoxification; recommended dose 380 mg every 4 weeks (Section 1.2 and Section 2.1).
Before starting Vivitrol, clinicians check that the person is not actively using opioids.
For opioid dependence: patients should be opioid-free before starting VIVITROL (Section 5.3).
Before starting Vivitrol, clinicians check that the person has no signs of opioid withdrawal.
Label discusses preventing precipitated withdrawal and requires patients dependent on opioids be opioid-free before starting (Section 5.3). (Specific “signs of opioid withdrawal” phrase not shown, but withdrawal prevention requirement is on-label.)
Naltrexone can precipitate withdrawal in someone with opioids in their system.
Label: precipitation of opioid withdrawal when opioid antagonist administered to opioid-dependent patient (Section 5.3).
Prescribers may use an opioid-free interval and/or other assessment steps per clinical practice and product guidance before starting treatment.
Label recommends an opioid-free interval of minimum 7–10 days (Section 5.3) and indicates patients should be opioid-free at time of dose administration (Section 2.3).
Incorrect route or poor technique can increase the risk of adverse effects from improper administration.
Label states VIVITROL must be prepared and administered by a healthcare provider and only as a deep IM gluteal injection; serious outcomes including injection site reactions have been reported following patient self-administration (Section 2.1 and Section 6.2).
Vivitrol should only be administered by a clinician or a trained caregiver following the official prescribing information and injection instructions.
Label: must be prepared and administered by a healthcare provider and must ONLY be administered as deep intramuscular gluteal injection (Section 2.1).
Unsupported Statements
Vivitrol is not a pill.
The provided label excerpts specify administration as a deep intramuscular gluteal injection, but the claim “not a pill” is not stated verbatim in the supplied label text.
Vivitrol is not meant for subcutaneous (under the skin) use.
The label excerpt states only deep intramuscular gluteal injection is allowed (Section 2.1), but it does not explicitly mention “subcutaneous.”
Vivitrol is not meant for IV (into a vein) use.
The label excerpt specifies deep intramuscular gluteal injection only (Section 2.1), but it does not explicitly mention “IV.”
Incorrect route or poor technique can lead to failed dosing (less medication delivered than intended).
The provided label excerpts do not describe “failed dosing” as an outcome of incorrect route/technique.
Incorrect route or poor technique can lead to local injection-site complications such as pain, swelling, lumps, and increased infection risk.
Label excerpt confirms injection site reactions occur (Section 6.2) but does not specifically enumerate pain/swelling/lumps or mention increased infection risk, nor does it attribute these specifically to incorrect technique/route.
Correct IM injection requires correct needle length, correct angle, and correct handling of the suspension so the dose is delivered correctly.
The provided label excerpts include preparation/administered by a healthcare provider and deep IM gluteal injection only, but do not include the specific needle length/angle/suspension-handling details in the supplied text.
Contradictions
Low
AI Statement
Vivitrol is administered as an extended-release intramuscular (IM) injection.
Label Reference
Section 2.1 specifies “deep intramuscular gluteal injection.”
Important Omissions
Dose administration timing nuance: label recommends an opioid-free interval of minimum 7–10 days (Section 5.3) and states patients reinitiating treatment should be opioid-free at the time of dose administration (Section 2.3). The claims reference “opioid-free interval” generally but do not capture the stated minimum 7–10 day recommendation.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Core safety elements are captured (deep IM-only administration; opioid-free requirement; risk of precipitated withdrawal; healthcare-provider administration). However, some claims about subcutaneous/IV routing, injection-site complications (including infection risk), and failed dosing due to technique are not specifically supported in the provided label excerpts, and the minimum opioid-free interval timing is not stated.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Some administration/complication mechanism details are not explicitly supported by the provided label excerpts (needle length/angle/suspension handling; failed dosing; infection risk). Minimum 7–10 day opioid-free interval is not stated.
Suggested Improvement
Rephrase unsupported technique-specific and infection-risk/failure-dose statements to match label language: “must be prepared and administered by a healthcare provider” and “ONLY deep intramuscular gluteal injection” (Section 2.1), and include the on-label “minimum 7–10 days” opioid-free interval (Section 5.3).